+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Next Generation Cancer Diagnostics: Technologies and Global Markets

  • PDF Icon

    Report

  • 166 Pages
  • May 2023
  • Region: Global
  • BCC Research
  • ID: 5138101

This research report analyzes leading next-generation diagnostic technologies, including next generation sequencing (NGS), polymerase chain reaction (PCR), multiplex conventional, cell or extracellular vesicle capture, and arrays/microfluidics. The report also discusses various liquid biopsy platforms and how these compare with tissue-based testing.

The report discusses several significant, large-scale research initiatives contributing to cancer diagnostic development. Key forces driving the market are discussed.

An in-depth analysis of key companies operating in the next-generation cancer diagnostic and technologies market is also included. The information also focuses on companies involved in developing products and emerging technologies.

The market for next-generation cancer diagnostics is analyzed in depth. The market is analyzed by cancer site (bladder, brain, breast, colorectal, cancer of unknown primary, gastric, gynecologic, hematologic, kidney, liver, lung, pan-cancer, pancreatic, prostate, melanoma, and thyroid), by test purpose (screening/early detection, diagnosis, monitoring, therapy guidance), by test platform (arrays/microfluidics, cell/EV capture, multiplex conventional, PCR and NGS) and by geography (North America, Europe, Asia-Pacific, and Rest of World).

The base year for market data is 2021, with historical data provided for 2020 and 2019 and forecast data provided through 2027. Historical, base year, and forecast data are provided for each market segment of the report.

Report Includes

  • 15 data tables and 80 additional tables
  • An overview of the global market and technologies for next generation cancer diagnostics
  • Estimation of the market size and analyses of global market trends, with data from 2021, estimates for 2022 and projections of compound annual growth rates (CAGRs) through 2027
  • Highlights of the current and future market potential and quantification of next generation cancer diagnostics market based on type, application, and region
  • Description of arrays and microfluidics (LOAC) technologies, multiplex conventional technologies, next generation sequencing technology and polymerase chain reaction (PCR) technology
  • Analysis of underlying technological, environmental, legal/regulatory, and political trends that may influence the size and nature of the market
  • Coverage of the key initiatives and programs related to the next generation cancer diagnostics market
  • Market share analysis of the key companies of the industry and coverage of their proprietary technologies, strategic alliances, and other key market strategies
  • Company profiles of major players within the industry, including Abbott Laboratories, Illumina Inc., Becton, Dickinson and Co., and Illumina Inc.

Table of Contents

Chapter 1 Introduction
1.1 Study Goals and Objectives
1.2 Reasons for Doing this Study
1.3 Scope of Report
1.4 What's New in this Update?
1.5 Information Sources and Methodology
1.5.1 Secondary Research
1.5.2 Primary Research
1.6 Research Methodology
1.7 Geographic Breakdown
1.8 Analyst's Credentials
1.9 Custom Research
1.10 Related Research Reports

Chapter 2 Summary and Highlights
Chapter 3 Market and Technology Background
3.1 Overview
3.2 Next Generation Sequencing in Personalized Medicine
3.2.1 Cost-Effective
3.2.2 Samples Required
3.3 NGS in Clinical Oncology
3.3.1 Accurate Detection of Genetic Mutations
3.3.2 Precision Diagnostics
3.3.3 Tumor Genomic Profiling
3.4 Large-Scale Initiatives and Consortia
3.5 Liquid Biopsy Technologies
3.6 Liquid Biopsy as a Market-Driving Force
3.6.1 Key Trends
3.7 Industry
3.8 Diagnostics Overview
3.9 Arrays and Microfluidics (Loac) Technologies
3.9.1 Dna Microarrays
3.9.2 Protein Microarrays
3.9.3 Microfluidics
3.10 Multiplex Conventional Technologies
3.11 Polymerase Chain Reaction (Pcr) Technology

Chapter 4 Cancer Diagnostics Market
4.1 Forces Driving Growth
4.2 Cancer Markets
4.3 Market for Next-Generation Cancer Diagnostics by Cancer Site
4.3.1 Bladder Cancer
4.3.2 Brain Cancer
4.3.3 Breast Cancer
4.4 Market for Next-Generation Cancer Diagnostics by Purpose of Analysis
4.4.1 Screening/Early Detection Market
4.4.2 Diagnostics Market
4.4.3 Therapy Guidance Market
4.4.4 Monitoring Market
4.5 Market for Next-Generation Cancer Diagnostics by Test Platform
4.5.1 Pcr Test Platform
4.5.2 NGS Test Platform
4.5.3 Array/Microfluidics Test Platform
4.5.4 Cells And/Or Ev Capture Test Platform
4.5.5 Multiplex Conventional Test Platform
4.6 Market for Test Platforms by Cancer Site
4.6.1 Pcr Test Platform
4.6.2 NGS Test Platform
4.7 Market by Diagnostic Segment
4.7.1 Screening/Early Detection Market
4.7.2 Diagnostics Market
4.7.3 Monitoring Market
4.7.4 Therapy Guidance Market
4.7.5 Breast Cancer Diagnostics
4.7.6 Digestive Cancer Diagnostics
4.7.7 Respiratory and Skin Cancer Diagnostics

Chapter 5 Market Breakdown Application by Cancer Site
5.1 Overview
5.2 Bladder Cancer
5.3 Brain Cancer
5.3.1 Types of Brain Cancer
5.4 Breast Cancer
5.4.1 Risk
5.4.2 Breast Cancer Screening
5.4.3 Prognosis and Pharmacogenetics Tests
5.4.4 Breast Cancer Mdx Platforms
5.4.5 Status of Next-Generation Breast Cancer Tests
5.4.6 Treatment
5.5 Gynecologic Cancers
5.5.1 Cervical Cancer
5.5.2 Ovarian Cancer
5.6 Colorectal Cancer
5.6.1 Conventional Colorectal Cancer Screening Tests
5.6.2 Next-Generation Colorectal Cancer Diagnostic Tests
5.7 Cancer Unknown Primary
5.8 Gastric Cancer
5.9 Kidney Cancer
5.10 Hematologic Tests: Leukemia and Myeloma
5.11 Liver Cancer
5.12 Lung Cancer
5.13 Hematologic Tests: Lymphomas
5.14 Melanoma
5.15 Pan-Cancer
5.16 Prostate Cancer
5.17 Thyroid Cancer

Chapter 6 Emerging Technologies
6.1 Overview
6.2 Population Sequencing Programs
6.3 Introduction
6.4 Crispr

Chapter 7 Evaluation of the Market Based on Geographic Region
7.1 Overview of the Geographical Distribution of the Market
7.2 Overview
7.3 North America
7.4 Europe
7.5 Asia-Pacific
7.6 Rest of the World

Chapter 8 Patents
Chapter 9 Company Profiles
  • Abbott Laboratories
  • Abbvie Inc.
  • Advanced Cell Diagnostics Inc.
  • Agilent Technologies
  • Artivion Inc.
  • Becton, Dickinson and Co.
  • Benitec Biopharma Ltd.
  • Caladrius Biosciences
  • Celgene Corp.
  • Commence Bio
  • Depuy Synthes (J&J)
  • Drägerwerk AG & Co. Kgaa
  • Epic Sciences Inc.
  • Genexine
  • Geron
  • Illumina Inc.
  • Immunocellular Therapeutics
  • Inex Innovations Exchange Pte. Ltd.
  • Inivata Ltd.
  • Interpace Diagnostics LLC
  • Invivoscribe Inc.
  • Medtronic plc
  • Merck Kgaa
  • Novartis AG
  • Oncocyte Corp.
  • Oncomed Pharmaceuticals Inc.
  • Pluristem Therapeutics Inc.
  • Silicon Biosystems S.P.A
  • Sphere Fluidics Ltd.
  • Thermo Fisher Scientific
  • Vitatex Inc.
List of Tables
Summary Table: Global Market for Next-Generation Cancer Diagnostics, by Cancer Site, Through 2027
Table 1: Large-Scale Initiatives: Cancer Diagnostics Industry
Table 2: Liquid Biopsy Biomarker Classes
Table 3: Key Trends in the Market for Next-Generation Cancer Diagnostics
Table 4: Next-Generation Cancer Diagnostics Industry Subsectors
Table 5: Diagnostic Market Segments
Table 6: Next-Generation Diagnostics: Key Analysis Platforms
Table 7: Analysis Platforms and Biomarker Types
Table 8: DNA Microarray Technologies in Cancer Diagnostics
Table 9: Design Features of Protein Microarray Technologies
Table 10: Microfluidic LOAC Types Used in Cancer Diagnostics
Table 11: Advanced Sequencing Technologies
Table 12: Illumina Next Generation Sequencing Workflow
Table 13: Thermo Fisher Scientific’s Next-Generation Sequencing Workflow
Table 14: Main Ingredients of PCR Technology
Table 15: PCR Process
Table 16: Advantages of Droplet Digital PCR for Single-Cell Analysis
Table 17: Liquid Biopsy: Forces Driving Growth, 2020
Table 18: Limitations of Solid Biopsy in Cancer Applications
Table 19: Low-Frequency Mutation Detection
Table 20: Global Market for Next-Generation Cancer Diagnostics, by Cancer Site, Through 2027
Table 21: Global Market for Next-Generation Cancer Diagnostics, by Purpose of Analysis, Through 2027
Table 22: MRI and Liquid Biopsy Methods
Table 23: Early Detection: Tissue of Origin Approaches
Table 24: Global Market for Next-Generation Cancer Diagnostics, by Test Platform, Through 2027
Table 25: FDA-Approved or CE-Marked Tests with Epigenetic Component
Table 26: Global Market for PCR-Based Cancer Diagnostics, by Cancer Site, Through 2027
Table 27: Global Market for NGS-Based Cancer Diagnostics, by Cancer Site, Through 2027
Table 28: Global Market for Next-Generation Cancer Screening/Early Detection, by Cancer Site, Through 2027
Table 29: Global Market for Next-Generation Cancer Diagnostics, by Cancer Site, Through 2027
Table 30: Global Market for Next-Generation Cancer Monitoring, by Cancer Site, Through 2027
Table 31: Global Market for Next-Generation Cancer Monitoring, by Cancer Site, Through 2027
Table 32: Global Market for Breast Cancer Diagnostics, by Analysis Method, Through 2027
Table 33: Global Market for Digestive Cancer Diagnostics, by Analysis Method, Through 2027
Table 34: Global Market for Respiratory and Skin Cancer Diagnostics, by Analysis Method, Through 2027
Table 35: Bladder Cancer Diagnostic Tests, 2020
Table 36: Brain Cancer: Next-Generation Diagnostics Tests, 2020
Table 37: Annual Breast Cancer Treatment Decisions, U.S., by Cancer Classification
Table 38: Breast Cancer MDx Technology Platforms
Table 39: Next-Generation Breast Cancer Tests, 2020
Table 40: Next-Generation Human Papilloma Virus and Cervical Cancer Screening and Genotyping Tests
Table 41: Ovarian Cancer Early Screening Formats, 2020
Table 42: Ovarian Cancer: Next-Generation Diagnostics Tests, 2020
Table 43: CRC Screening Tests
Table 44: Colorectal Cancer: Next-Generation Diagnostic Tests
Table 45: Cancer Unknown Primary: Next-Generation Diagnostic Tests, 2020
Table 46: Gastric Cancer: Next-Generation Diagnostic Tests, 2020
Table 47: Kidney Cancer: Next-Generation Diagnostic Tests, 2020
Table 48: Leukemia and Myeloma: Next-Generation Diagnostic Tests, 2020
Table 49: Liver Cancer: Next-Generation Diagnostic Tests, 2020
Table 50: Five-Year Survival Rates for Non-Small Cell Lung Cancer
Table 51: Lung Cancer: Next-Generation Diagnostic Tests, 2020
Table 52: Lymphoma: Next-Generation Diagnostic Tests, 2020
Table 53: Melanoma: Next-Generation Diagnostic Tests, 2021
Table 54: Pan-Cancer: Next-Generation Diagnostic Tests, 2020
Table 55: Prostate Cancer Next-Generation Diagnostic Tests
Table 56: Thyroid Cancer: Next-Generation Diagnostics Tests, 2020
Table 57: R&D: Next-Generation Cancer Diagnostics
Table 58: Population Sequencing Projects
Table 59: Global Market for Next-Generation Cancer Diagnostics, by Region, Through 2027
Table 60: Select Patent Applications Filed on Next-Generation Cancer Diagnostics Technologies
Table 61: Abbott Laboratories: Product Portfolio
Table 62: Abbott Laboratories: Developments 2020-2022
Table 63: AbbVie: Oncology Pharmaceutical Products Portfolio
Table 64: AbbVie: Marketed Products
Table 65: AbbVie: Key Developments, 2020-2021
Table 66: Allergan plc: Marketed Products
Table 67: Advanced Cell Diagnostics: Product Portfolio
Table 68: Agilent Technologies: Developments, 2019-2022
Table 69: Artivion Inc.: Product Portfolio
Table 70: Artivion Inc.: Developments, 2020
Table 71: Becton, Dickinson and Co.: Company Financials, 2021
Table 72: Becton, Dickinson and Co.: Product Portfolio
Table 73: Becton, Dickinson and Co.: Developments, 2017-2022
Table 74: Benitec Biopharma: Product Portfolio
Table 75: Caladrius Biosciences: Product Portfolio
Table 76: Celgene Corp.: Product Portfolio
Table 77: Commence Bio: Product Portfolio
Table 78: DePuy Synthes: Product Portfolio
Table 79: DePuy Synthes: Developments, 2019-2022
Table 80: Dräger: Product Portfolio
Table 81: Epic Sciences: Product Portfolio
Table 82: Genexine: Product Portfolio
Table 83: Geron: Product Portfolio
Table 84: ImmunoCellular Therapeutics: Product Portfolio
Table 85: Medtronic plc: Developments, 2019-2022
Table 86: Novartis: Developments, 2019 and 2020
Table 87: OncoCyte: Product Portfolio
Table 88: OncoMed: Product Portfolio
Table 89: Pluristem Therapeutics: Product Portfolio
Table 90: Silicon Biosystems: Product Portfolio
Table 91: Sphere Fluidics: Product Portfolio
Table 92: Thermo Fisher Scientific: Product Portfolio
Table 93: Thermo Fisher Scientific: Developments, 2019-2022
Table 94: Vitatex: Product Portfolio

List of Figures
Summary Figure: Global Market for Next-Generation Cancer Diagnostics, by Cancer Site, 2019-2027
Figure 1: Distribution of Cases by Stage at Diagnosis: Female Breast Cancer, 2021
Figure 2: Global Incidence and Prevalence of Cancer Cases, by Cancer Site, 2022
Figure 3: Snapshot of Next-Generation Cancer Diagnostics Technologies, by Region
Figure 4: Global Market Shares of Next-Generation Cancer Diagnostics Technologies, by Region, 2027
Figure 5: Becton, Dickinson and Co.: Revenue Share, by Business Segment, 2021
Figure 6: Illumina Inc.: Annual Revenue, 2018-2021
Figure 7: Illumina Inc.: Revenue Share, by Region/Country, 2021
Figure 8: Illumina Inc.: Revenue Share, by Product Segment, 2021

Executive Summary

An increasing number of cancer cases globally is one of the significant factors contributing to industry growth during the forecast period. Technological advancements in diagnostic tests are further expected to fuel industry growth. Moreover, supportive government initiatives and rising awareness are additional factors anticipated to boost growth during the forecast period. For instance, the Biden-Harris administration has set a goal of decreasing the cancer mortality rate by 50% over the next 25 years and enhancing the knowledge surrounding people living with and surviving tumors.

Cancer is one of the leading causes of death worldwide, and the prevalence of the disease has been escalating at an alarming rate. Therefore, healthcare professionals are focusing on developing effective screening and treatment solutions to check prevalence levels. Early screening increases the success rate of treatment regimens. As a result, healthcare agencies and market players, through various awareness programs, are promoting routine check-ups and screenings. For instance, in March 2022, HHS announced funding of $5 million to improve equity in cancer screening at health centers.

The global oncology burden is projected to reach 28.4 million cases in 2040, a 47% growth from 2020. Thus, a rise in the incidence is anticipated to boost the adoption of cancer diagnostic products. In April 2022, the Precision Cancer Consortium (PCC) collaborated with pharmaceutical companies by permitting access to comprehensive testing for all cancer patients globally. The PCC drives diverse initiatives to grow patient access to precision diagnostics using wide-ranging genomic testing, including next generation sequencing (NGS). The founding members of PCC include Novartis, Bayer, Roche, and GlaxoSmithKline.

Advanced diagnostics for cancer represent a significant market opportunity for life sciences companies. Many cancer types are on the rise as the aging populations of many countries continue to grow. As a result, there is an increasing demand for noninvasive diagnostic assays that can detect cancers earlier, molecularly subtype tumors to guide therapy decisions and monitor cancer recurrence in treated individuals.

Cancer remains the second leading cause of death worldwide despite advances in treatment. Cancer takes a tremendous toll on patients, families, and society. One pressing need in cancer diagnostics is earlier-stage identification, identifying cancer before it has spread to other body parts. Several companies are using advanced diagnostic platforms to develop and validate assays that detect cancer earlier to meet this need. Sanomics, Prenetics, Guardant, Thrive Earlier Detection, AnPac BioMedical, and Grail are notable examples.

A second pressing need in cancer is a more accurate classification of suspicious lesions or nodules (malignant or benign). Correct type leads to better treatment decisions and fewer unnecessary, invasive biopsies. In the case of lung cancer, peripheral lung nodules are very difficult to biopsy, deep within the small branches of the lung, often beyond the reach of the bronchoscope. Needle biopsy is problematic, carrying the risk of lung collapse and infection. New, non-invasive blood-based tests are needed to assess nodules.

Companies Mentioned

  • Abbott Laboratories
  • Abbvie Inc.
  • Advanced Cell Diagnostics Inc.
  • Agilent Technologies
  • Artivion Inc.
  • Becton, Dickinson and Co.
  • Benitec Biopharma Ltd.
  • Caladrius Biosciences
  • Celgene Corp.
  • Commence Bio
  • Depuy Synthes (J&J)
  • Drägerwerk AG & Co. Kgaa
  • Epic Sciences Inc.
  • Genexine
  • Geron
  • Illumina Inc.
  • Immunocellular Therapeutics
  • Inex Innovations Exchange Pte. Ltd.
  • Inivata Ltd.
  • Interpace Diagnostics LLC
  • Invivoscribe Inc.
  • Medtronic plc
  • Merck Kgaa
  • Novartis AG
  • Oncocyte Corp.
  • Oncomed Pharmaceuticals Inc.
  • Pluristem Therapeutics Inc.
  • Silicon Biosystems S.P.A
  • Sphere Fluidics Ltd.
  • Thermo Fisher Scientific
  • Vitatex Inc.

Table Information